Champions Oncology Q4 2023 Earnings Call Transcript

Quartr
Provided by Quartr
July 24, 2023

There are 3 speakers on the call.

Operator

Greetings and welcome to Champion Oncology's 4th Quarter and Fiscal Year End 2023 Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I I will now turn the conference over to your host, Ronnie Morris, CEO of Champions Oncology.

Operator

You may begin.

Speaker 1

Good afternoon. I'm Ronnie Morris, CEO of Champions Oncology. Joining me today is David Miller, our Chief Financial is available on Forms 10Q and Form 10 ks. A reconciliation of non GAAP financial measures that may be discussed during the call to GAAP financial measures is available earnings release. Overall, we had another year of progress, successfully expanding our business, core capabilities and platforms, while continuing to evolve and deliver on our longer term strategy.

Speaker 1

However, the year also presented several challenges as our business was adversely impacted primarily on 2 one external and one internal. As we discussed over the course of the year, the negative funding pressure on the biotech sector impacted our quarterly booking numbers in the first half of the year, early booking numbers in the first half of the year leading to a decline in sequential quarterly increases in our Q2. Additionally, along with the bookings decline in Q2, a challenging economic environment resulted in an uptick in customer cancellations. While the rate of cancellations has steadied, Our cancellation rate is still above historical norms as customers are still experiencing budgetary pressures and therefore are quicker to cancel studies than in the past. Internally, we encountered operational issues during the course of the year.

Speaker 1

These operational issues led to study delays, which resulted in lower than expected revenue conversion and was another contributor to the increase in cancellations. While we profitability. We anticipate that we will still feel the effects of these issues for the first half of this year and are looking forward to getting back on track to a robust profitability in the second half of this year. On a more positive note, despite these negative events, our bookings reaccelerated in the second half of last year and the trend has continued into the beginning of this fiscal year. As part of our longer term plan, we have expanded our core services including the continued development of our ex vivo platform.

Speaker 1

We feel that we have reached the next phase of development in our Nextiva platform and we are expecting these services to be a driver of revenue growth. Similarly, we have made some Our business development team to support our clinical services. With this team, we have already seen an increase in opportunity generation, which should lead to increased sales over the course of this fiscal year. With regard to our drug development effort, we recently announced the launch of our therapeutic discovery and development platform into a wholly owned subsidiary named the Corellia AI. Corellia launched out of Champions discovery and development platform.

Speaker 1

It will continue to leverage Champion's superior PDX molecular Atlas and its living bank of PDX models as central tools in its proprietary target and therapeutic discovery program. Our objective to develop innovative first in class antibody drug conjugates at a more rapid pace and with greater efficiency. Our lead discovery programs are progressing to support and accelerate the growth of Harelia. In summary, despite this being a more challenging year than we expected, we have robust bookings, last year will spill over and continue to impact on our results in the first half of this fiscal year, but we are confident that we are poised to emerge with stronger revenue and profitability over the longer term. Now let me turn the call over to David Miller for a more detailed

Operator

Thanks, Ronny. Full results on Form 10 ks will be filed with the SEC later today. We had another year of top line revenue growth with record revenue of approximately $54,000,000 representing year over year growth of 10% and within the revised range of the guidance provided. The issues Ronnie presented impacted performance leading to a growth rate below our historic norm and which contributed to the net loss for the year. On a GAAP basis, Our loss from operations for fiscal year 2023 was $5,300,000 compared to income of $607,000 in the prior year.

Operator

Included in the $5,300,000 loss are non cash expenses totaling $3,900,000 which includes stock comp depreciation and an impairment charge. The impairment charge of $800,000 was due to writing off the remaining capitalized cost of our Rouxman product. Excluding these non cash items, our adjusted loss was $1,300,000 for 2023 compared to adjusted EBITDA of $3,100,000 in the year ago period. Turning the focus to the 4th quarter and cash based results. 4th quarter revenue increased to was $13,100,000 compared to $12,900,000 in the year ago period, an increase of $200,000 or 2%.

Operator

Our adjusted loss was $920,000 compared to adjusted EBITDA of $445,000 in the year ago period. Total cost of sales was $7,100,000 compared to $6,000,000 in our Q4 last year, an increase of 18%. For the year, cost of sales was $28,800,000 compared to $23,200,000 a year ago, an increase of 24%. The increase for both the Q4 and full fiscal year compared to the same period last year was primarily due to increases in compensation as we staff our operational team to meet the anticipated bookings growth, which did occur, but which did not convert to revenue at the pace expected. Due to the increase in cost of sales on lower than expected revenue growth, our gross margins for the 4th quarter and year end were under pressure, coming in at 45% for the quarter and approximately 47% for the year.

Operator

For the same period last year, gross margin was approximately 53%. The margin pressure will continue for the first half of twenty twenty four as our revenue conversion percentage is still expected to be below our historical rate. As revenue conversion improves, we anticipate an expansion of our gross margin in the second half of this year. For the Q4, R and D expense was approximately $2,900,000 compared to $2,600,000 in the year ago period. For the year, R and D expense was $11,500,000 compared to 9,300,000 fiscal 2022.

Operator

The year over year $2,200,000 increase was attributed to our stated strategy to ramp up our R and D spend, specifically investing in our drug discovery platform. For the 4th quarter, sales and marketing expense was $1,800,000 an increase of was $200,000 compared to the Q4 of last year. For the year, sales and marketing expense was $6,800,000 compared to $6,200,000 in the year ago period. The increases were primarily attributed to compensation expense related to the expansion of our business development team and additional marketing initiatives such as constant dependence as COVID restrictions ease. Our G and A expense was $2,200,000 for both the Q4 of 2023 2022.

Operator

For the year, G and A expense was $8,100,000 compared to $7,200,000 in the year ago period. This was primarily due to an increase in IT and professional fees. We invested in upgrading our IP infrastructure to support company growth and the professional fees related to the formation of our new subsidiary. Looking ahead to fiscal year 2024, we anticipate a lower level of G and A increases and G and A as a percentage of revenue is expected to decline. Now turning to cash.

Operator

We ended the year with $10,100,000 of cash on the balance sheet and no debt. For the quarter, cash used in upgrading activities were $700,000 with an additional $760,000 for investment in lab equipment and $75,000 in financing activities as part of our stock repurchase plan. For the year, cash generated by operating activities of $4,000,000 and cash used for CapEx was approximately $3,000,000 Looking ahead to fiscal year 2024, We anticipate a decline in our cash balance over the first half of the year, but with the continued strength in our bookings and as we improve our revenue conversion, our cash position will rebound. Our planned CapEx spend is in the $2,500,000 range as we further automate our extrema platform and other lab functions to increase capacity and improve efficiencies, allowing us to increase our revenue and expand our margin. Information.

Operator

Our financial performance for 2023 was impacted by the challenges outlined in this call. However, Despite the challenges, we reached another annual revenue record recording approximately $54,000,000 in revenue and growing by 10%. Our bookings rebounded from a small decline in the 2nd quarter, reaching new highs in the second half of the year. We anticipate continued strength in our bookings over the course of fiscal 20 before. We're projecting revenue growth for the year to be between 5% 15%.

Operator

The rationale for the wide range is that it's difficult to pinpoint the exact timing of the improvement of our revenue conversion, although we are expecting the revenue conversion to revert back to historical norms in the latter half of the year. I want to reiterate their message that despite some short term obstacles, our long term prospects are positive. Our sales are strong and we are positioned to capitalize on the exciting long term opportunities that lie ahead. We look forward to another update in about 6 weeks when we report our Q1 results. We will now open the call for questions.

Operator

Thank you. At this time, we will be conducting a question and answer A confirmation tone will indicate your line is in the question And the first question today is coming from Matt Hewitt from Craig Hallum. Matt, your line is live.

Speaker 2

Good afternoon. Thank you for taking the questions and for the update. Maybe first one, just regarding the landscape. It sounds like you're seeing some improvement, albeit Some cancellations are remaining a little bit elevated. Maybe if you could talk a little bit about what you're hearing from customers regarding their pipelines, regarding their desire to invest and keep moving the ball forward on some of those programs?

Speaker 2

Yes. Thanks, Matt. So, yes, we definitely over the last year have seen an increase in The willingness of customers to be more quick or changing their priorities fairly quickly, but based on their feelings and their budgetary feelings of when they're going to be able to raise new capital. That's certainly been a factor in terms of the cancellations. We feel at least now that things have stabilized.

Speaker 2

So I think we felt most of it maybe a couple of quarters ago. It's still happening, but we feel Like that is coming back into line. And I think more recently we just experienced some of these operational issues that have held back some studies and had And I think that that is contributing now. So it was a combination of I think 1st couple of quarters it was more customers there's still a mix, right? There's certainly still a mix.

Speaker 2

I think customers are more conscious of if the study isn't going well in terms of they're not getting the results they want early of maybe cutting part of the study out whereas in past they might have just rolled with whole study hoping for some better results in the latter half In the first half of the study, I think that they're now being quicker to say, hey, we're not seeing the Single we wanted maybe we'll pare back the study. So that's certainly been a phenomenon that we've seen over the last couple of quarters. Just anecdotally and just Augustealth, we're starting to feel things open up a little bit more where people are less pressurized and seem to be now seem to be more consistent with the way they behaved, let's say, a couple of years ago. Got it. And then maybe touching on the internal issues that kind of popped up.

Speaker 2

Could you provide a little bit of color on what those were and how those have been addressed? Yes. I think a lot of it started with a bunch of management changes that we had. Maybe about a year ago, we had some 1 or 2 key people from management, especially the in vivo side leave led to A couple of issues, a couple of some high turnover, not able to bring people on, train them in time, which led to delays, led to a couple of deviation led to some higher of deviations than we've been accustomed to, which of course leads to having to restart studies, repeat studies and that also leads sometimes to customers It's going to take an extra couple of months now because the way it works with in vivo studies, it takes 6 months for an in vivo study. So if you have to start over, Oftentimes, either a study delay in the best of cases where the revenue is not going to be delayed by a long period of time or the customer is Going to say, maybe I'll use my dollars for some other purpose and just cancel the study.

Speaker 2

So We had a bunch of that. We have brought in, I think now strong management team. We've fixed a lot of the issues that we had experienced over a couple of months period. But because it's in vivo studies, it takes a while to wash out some of those issues. So Because these studies go on for a long time and that the revenue is a long cycle, It just takes a little bit of time for us to be able to see the fruits of those labors.

Speaker 2

But we have it under control. We've known this a long time. And we now have the right people in place, the right processes in place, going back to the way we were, The right metrics in place and we're confident that this is just going to be a short blip. Got it. All right.

Speaker 2

Maybe one last one then I'll hop back in the queue. But I was wondering if you could give us an update on the Alloy Therapeutics partnership, how that's progressing? Any details there? Thank you. Yes.

Speaker 2

So the Allo partnership is building antibody drug conjugates. That's really in the Karelia, which has been carved out as a wholly owned That we're out there raising money for. We're excited about it. We have really good data and we're talking to a bunch of prospective investors at this time. So, all things leading in the right direction, We feel like Allied has done some real quality work, building the ADCs against our targets And we're excited about the position that we're currently in.

Speaker 2

Great. Thank you.

Operator

Thank you. The next question is coming from Scott Henry from ROTH Capital. Scott, your line is live. Thank you and good afternoon. And just a couple of questions.

Operator

First, you mentioned year over year bookings were up and the Q4. Can you give us a baseline for that? What was that number in the first, second and third quarters, so we can kind of put that into context?

Speaker 2

So I think what we mentioned was year over year the bookings were up 14%. I don't think we mentioned correct me if I'm wrong, David, I don't think we mentioned It's both. No, it's both.

Operator

It's both. There was both Same percentage. So comparing Q4 to Q4, they were up 50% comparing year over year, it's 15%. Okay.

Speaker 1

It

Operator

just happens to be the same number. But in general, we don't Our exact bookings number, we're just indicating the strength in our booking remains. And yes, I know to To answer the question specifically, we have not provided a specific bookings numbers over our history. I don't know if you want to ask that. So it sounds Okay.

Operator

I'm just trying to get a sense of that number outside of isolation. It sounds like it was within the typical range Perhaps the higher end, but that's good. 2nd, David, I think you said 5% to 15 percent revenue growth in fiscal 2024. When we think about the first half versus the second half, it sounds like The first half would be the lower end of that range. The second half the higher end of that range is that fair?

Operator

Correct. That's fair. Okay. Thank you. And then you're getting into the AI business, Certainly in the drug discovery channel.

Operator

Is AI also a threat to your business? I mean, how do you think about what AI could do to the core business, if at all or perhaps you can even do more with it and make it more appealing?

Speaker 2

Yes. So I think that AI actually enhances the business. I think any time there's tools whether it was the genomic Explosion now the proteomic explosion, the transcriptomic explosion, now using all of that and using AI to find new hypotheses. I think any time we use new tools to investigate information, what ends up happening is we come up with new hypotheses and pharma and biotech come up with all new ideas and interesting ideas. And that leads to more discovery, More investment, more need to test the hypothesis.

Speaker 2

So I actually think that both AI is helping us and has helped us come up with new targets and it's helping a lot of other people come up with new targets. So From my perspective on both, I think it's helpful to us and it's also helpful in the core business, because I think that it's just going to enhance and make more use of our services.

Operator

Okay. Great. Final question, which is A bit of a tougher one, but I think a relevant one. You've got a great core business. It's done well for multiple years.

Operator

You've invested in some new initiatives, which yet to be honest they haven't worked out as well as planned, which happens with new initiatives. But now you're starting to have some pain in the core business as well from execution. So the question is, do you think you're spreading yourself too thin? Could this Kurelya business actually help to maintain a shift separate between the core and the new initiatives? Thank you.

Speaker 2

Yes. Yes. I think that's a great question. So first of all, I think that we have tried to do a lot over many years, right? And certainly, we have expanded.

Speaker 2

And as you heard me talk about over the years, we expanded into data, trying to get into software. And I think that we have pared back over the last year or 2 and realized that we need to focus and concentrate on 2 kind of lines of business. 1 is the proprietary business that comes off of our proprietary bank, which is both our in vivo and our ex vivo platforms that really utilize the specialness of our tumor bank and all the data around our models. That still remains the bulk of our business and we're putting a tremendous amount of effort into our ex vivo platform. We're excited about The feedback we're getting, we're excited about the bookings we're getting in that ex vivo business.

Speaker 2

Then we have The tools that we use for that business, which is all the biomarker tools, flow cytometry, histology, sequencing and using those for either clinical or preclinical services standalone outside of people who utilize us for our tumor bank. And that's also starting to grow And that has been a little more tedious and it's been harder and there's more competition within that side of the business. However, I do believe over the long haul it's been harder than we expected and it's taken longer, but I feel like we're definitely making traction. It's definitely the right move for Champions to continue to push on that. And then for certain things that we felt it wasn't the right time even though it might have been a good idea And we might have had good technology.

Speaker 2

So for instance, like the software services in Lumin and we still have some users of Lumin and We still think it's a good platform, but we deemphasize that because there was a lot on our plate and there was too much on our plate. So I think that Carving out the discovery business into a separate business was another example of that. Like that has to stand alone that has a separate team. It's a separate head focus and that does have to stand on its and can't take the focus away from Champion. So I think we are very, very focused right now.

Speaker 2

I think we have Good people working on these areas. There's always challenges. But I think in these areas, I feel pretty confident that we're going to continue to grow and continue to be able to continue to expand Adjacent expansion into these what we call end to end preclinical services into the clinical services.

Operator

Okay, great. Thank you for the color and thank you for taking the question.

Speaker 2

My pleasure.

Operator

Thank you. There are no other questions in queue at this time. I would now like to turn the call back to Ronnie Morris for closing remarks.

Speaker 2

Thank you for everybody for joining our quarterly call. As we've said, we're still very excited about the platform. We're excited about The growth potential that we're going to have over the next couple of years, there are some challenging quarters ahead, But then we see line of sight to getting back to where we were in terms of robust profitability. We're also excited about the drug discovery effort that we have put into an entity and we're excited that we're out there raising money and the capital for with the Correlia initiative and we hope to have good news and be able to update everybody in the next couple of weeks on our Q1 call. Thank you for joining.

Operator

Thank you. This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.

Powered by Quartr
Earnings Conference Call
Champions Oncology Q4 2023
00:00 / 00:00